Psychopharmacology of smoking cessation in patients with mental illness.
Selby
Peter
P
Addictions Program, Centre for Addiction and Mental Health, Departments of Family and Community Medicine, Psychiatry and Public Health Sciences, University of Toronto, Toronto, Ont, Canada.
D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use*; D001007:Anxiety / Q000139:chemically induced* / Q000188:drug therapy; D001143:Arousal / Q000187:drug effects; D016642:Bupropion / Q000627:therapeutic use*; D015283:Citalopram / Q000627:therapeutic use*; D003863:Depression / Q000139:chemically induced* / Q000188:drug therapy; D003865:Major Depressive Disorder / Q000188:drug therapy*; D018765:Dopamine Uptake Inhibitors / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D008297:Male; D008875:Middle Aged; D016540:Smoking Cessation / Q000523:psychology*; D014029:Tobacco Use Disorder / Q000523:psychology / Q000534:rehabilitation*
D018687:Antidepressive Agents, Second-Generation; D018765:Dopamine Uptake Inhibitors; D016642:Bupropion; D015283:Citalopram